Biotechnology in the Development of Gene-Silencing Therapies
American Journal of Biotechnology · 31.12.2025 · 6 (6) · 11-15
DOI: 10.71465/ajbt3492 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Biotechnology, online erschienen am 31.12.2025. Verfasst von Olivia Harrison und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gene-silencing therapies, particularly RNA interference (RNAi) and CRISPR/Cas-based approaches, represent a promising class of therapeutic strategies aimed at modulating gene expression for the treatment of genetic diseases. Biotechnology has played a crucial role in the development of these therapies by advancing the understanding of molecular mechanisms of gene regulation, as well as improving delivery systems and safety profiles. This article explores the biotechnological innovations driving the development of gene-silencing therapies, including RNAi, CRISPR/Cas9, and antisense oligonucleotides, as well as their applications in treating genetic disorders. We also discuss the challenges in clinical implementation, regulatory considerations, and future prospects for gene-silencing therapies.
Zitieren
APA
Harrison, O., & Lee, M. (2025). Biotechnology in the Development of Gene-Silencing Therapies. American Journal of Biotechnology, 6(6), 11-15. https://doi.org/10.71465/ajbt3492
Vancouver
Harrison O, Lee M. Biotechnology in the Development of Gene-Silencing Therapies. American Journal of Biotechnology. 2025;6(6):11-15. doi:10.71465/ajbt3492
BibTeX
@article{Harrison2025,
author = {Harrison, Olivia and Lee, Marcus},
title = {Biotechnology in the Development of Gene-Silencing Therapies},
journal = {American Journal of Biotechnology},
year = {2025},
volume = {6},
number = {6},
pages = {11--15},
doi = {10.71465/ajbt3492}
}
EUVIMED